[1]孟淑华,魏军平.TSHR信号转导通路在Graves眼病发病机制中的作用[J].国际内分泌代谢杂志,2014,(02):84-86.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
 Meng Shuhua,Wei Junping..Roles of TSHR signal transduction pathway in Graves' ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2014,(02):84-86.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
点击复制

TSHR信号转导通路在Graves眼病发病机制中的作用()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年02期
页码:
84-86
栏目:
甲状腺疾病专栏
出版日期:
2014-04-30

文章信息/Info

Title:
Roles of TSHR signal transduction pathway in Graves' ophthalmopathy
作者:
孟淑华魏军平
100053 北京,中国中医科学院广安门医院内分泌科   
Author(s):
Meng ShuhuaWei Junping.
Department of Endocrinology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China Corresponding author:Wei Junping,Email:weijunping@126.com
关键词:
Graves眼病促甲状腺激素受体信号转导
Keywords:
Graves' ophthalmopathyThyroid stimulating hormone receptorSignal transduction
DOI:
10.3760/cma.j.issn.1673-4157.2014.02.004
摘要:
近年来Graves眼病发病率逐年上升,引起人们的广泛关注。目前该病的发病机制尚不明确。促甲状腺激素受体(TSHR)信号转导通路是Graves眼病发病的关键因素。文章综述了TSHR信号转导通路在Graves眼病发病机制中作用的相关研究,介绍了TSHR信号转导通路具体途径,以及在此基础上开发的能结合TSHR并阻断信号转导通路的低相对分子质量TSHR拮抗剂NCGC00229600,为治疗Graves眼病开创了新前景。
Abstract:
In recent years,the incidence of Graves' ophthalmopathy(GO) has increased greatly,and caused widespread concern. Currently,the pathogenesis of GO is unclear. Studies have shown that receptor of thyroid stimulating hormone(TSHR) and its signaling pathway are key factors in GO.Here reviews the research progress of TSHR signal transduction pathway in the pathogenesis of GO. NCGC00229600,a small molecule TSHR antagonist may have great promise in the treatment or prevention of GO in the future.

参考文献/References:

 [1] Kleinau G,Mueller S,Jaeschke H,et al. Defining structural and functional dimensions of the extracellular thyrotropin receptor region[J]. J Biol Chem,2011,286(25):22622-22631.  
[2] Kleinau G,Hoyer I,Kreuchwig A,et al. From molecular details of the interplay between transmembrane helices of the thyrotropin receptor to general aspects of signal transduction in family a G-protein-coupled receptors (GPCRs) [J]. J Biol Chem,2011,286(29):25859-25871.  
[3] Zhang L,Baker G,Janus D,et al. Biological effects of thy-rotropin receptor activation on human orbital preadipocytes[J]. Invest Ophthalmol Vis Sci,2006,47(12):5197-5203.  
[4] Douglas RS,Afifiyan NF,Hwang CJ,et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy[J]. J Clin Endocrinol Metab,2010,95(1):430-438.  
[5] Kumar S,Schiefer R,Coenen MJ,et al. A stimulatory thy-rotropin receptor antibody(M22) and thyrotropin increase in-terleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts[J]. Thyroid,2010,20(1):59-65.  
[6] Lehmann GM,Garcia-Bates TM,Smith TJ,et al. Regulation of lymphocyte function by PPARgamma:Relevance to thyroid eye disease-related inflammation[J].PPAR Res,2008,2008:895901.  
[7] Latif R,Morshed SA,Zaidi M,et al. The thyroid-stimulating hormone receptor:impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimer-ization,cleavage,and signaling[J] . Endocrinol Metab Clin North Am,2009,38(2):319-341,viii.  
[8] Allen MD,Neumann S,Gershengorn MC.Occupancy of both sites on the thyrotropin(TSH) receptor dimer is necessary for phosphoinositide signaling[J]. FASEB J,2011,25(10):3687-3694.  
[9] van Zeijl CJ,van Koppen CJ,Surovtseva OV,et al. Complete inhibition of rhTSH-,Graves' disease IgG-,and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist[J]. J Clin Endocrinol Metab,2012,97(5):E781-E785.
[10] van Zeijl CJ,Fliers E,van Koppen CJ,et al. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophos-phate signaling pathways[J]. Thyroid,2011,21(2):169-176.
[11] van Zeijl CJ,Fliers E,van Koppen CJ,et al.Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglob-ulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients[J]. Thyroid,2010,20(5):535-544.
[12] Zhang L,Bowen T,Grennan-Jones F,et al. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction[J]. J Biol Chem,2009,284(39):26447-26455.
[13] Kumar S,Nadeem S,Stan MN,et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy[J].J Mol Endocrinol,2011,46(3):155-163.
[14] Kumar S,Iyer S,Bauer H,et al. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts:inhibition by an IGF-I receptor blocking antibody[J]. J Clin Endocrinol Metab,2012,97(5):1681-1687.
[15] Tsui S,Naik V,Hoa N,et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease[J].J Immunol,2008,181(6):4397-4405.
[16] Smith TJ,Hegedüs L,Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy [J]. Best Pract Res Clin Endocrinol Metab,2012,26(3):291-302.
[17] Neumann S,Eliseeva E,McCoy JG,et al. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor[J]. J Clin Endocrinol Metab,2011,96(2):548-554.
[18] Neumann S,Pope A,Geras-Raaka E,et al. A drug-like antago-nist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts[J].Thyroid,2012,22(8):839-843.
[19] Turcu AF,Kumar S,Neumann S,et al.A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy[J]. J Clin Endocrinol Metab,2013,98(5):2153-2159.

相似文献/References:

[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]刘雨平,罗佐杰.促甲状腺激素受体在非甲状腺组织中的表达及意义[J].国际内分泌代谢杂志,2021,41(01):10.[doi:10.3760/cma.j.cn121383-20200509-05015]
 Liu Yuping,Luo Zuojie..Expression and significance of thyroid stimulating hormone receptor in extrathyroidal tissues[J].International Journal of Endocrinology and Metabolism,2021,41(02):10.[doi:10.3760/cma.j.cn121383-20200509-05015]
[3]余静雯 胡欣 叶向荣 陈彦 刘超.2021年欧洲甲状腺学会/欧洲Graves眼病专家组Graves眼病管理指南:解读与思考[J].国际内分泌代谢杂志,2022,42(04):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
 Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(02):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
[4]谭婕 徐书杭.IL-6受体及其受体抗体在Graves眼病中的作用研究进展[J].国际内分泌代谢杂志,2023,43(05):380.[doi:10.3760/cma.j.cn121383-20220731-07068]
 Tan Jie,Xu Shuhang..Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy[J].International Journal of Endocrinology and Metabolism,2023,43(02):380.[doi:10.3760/cma.j.cn121383-20220731-07068]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81173260) 通信作者:魏军平,Email:weijunping@126.com
更新日期/Last Update: 2014-03-20